

# MDS 2020

## Paient Discussion Forum

A patient with LR-MDS who progressed

**Merav Barzilai** & Moshe Mittelman

Tel Aviv Sourasky Medical Center

# Patient EB, Paris (I)

---

## ■ 07/2016:

- A 65 yo female, fatigue
- Macrocytic anemia
- **PMH:** Bariatrics; Peptic d.; Smoking
- **PE:** unremarkable; ECOG 0
- **CBC:**
  - Hb 10.1; MCV 109; WBC 5.5; ANC 2.0;
  - PLT 492k !
- **BM:** Er + Meg dysplasia; LR-MDS
- **Cytogenetics:** del(5q)

# Patient EB, Paris (II)

---

- **Dg:** LR-MDS, del(5q) Syndrome
- **Hb declines – 7.1**
  - RBC transfusions
- **Treatment:**
  - AraNesp 150 micg/wk
    - Then – 300 micg/wk
    - Then - 500 micg/wk
- **Response**
  - RBC independent

# Patient EB (III), Israel

---

- 11/2016: Aliya (Immigration) to Israel
  - Hb continue to rise 11.8
- 7/2017: Hb declines – RBC transfusions
- 7/2017: Lenalidomide (10mg qd) – Hb 13.3
- 7/2018: Loss of response; RBC dependent
  - BM: 3-L dysplasia, 7% blasts
  - Cytogenetics: del(5q) + 20q-
  - Treatment: Aza + Pevonedistat
- 11/2018: CR

# Patient EB (IV)

---

- 11/2018: CR
- 01/2019: CR (RBC independent)
- 03/2019:
  - RBC dependent (again)
  - BM: Hypercellular, 3-lineage dysplasia,
  - 7% blasts; cytogenetics: del (5q)
- 06/2019: Rigosertib
- 08/2019: Decreased RBC requirements
  - BM: No blasts, but increased reticulin

# Patient EB (V)

---

- 11/2019:
  - RBC dependent (2u/m)
  - CBC: Hb 8.1; MCV 83; WBC 6.7; ANC 4.6  
PLT 214k
  - BM:
    - BM blasts 0-1%
    - Eosinophils 6%; Basophils 3%
    - BM fibrosis grade II-III : MF
  - Cytogenetics:
    - Del (5q); +21 (trisomy)

# Patient EB:

---

- Diagnosis ?
  - MDS/MPN ?
- Cause ?
  - Natural course ?
  - Drug related ?
- Treatment ?
  - SCT ?